COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use
- Normal Liver Cells Found to Promote Cancer Metastasis to the Liver
- Nearly 80% Complete Remission: Breakthrough in ADC Anti-Tumor Treatment
- Vaccination Against Common Diseases May Prevent Dementia!
- New Alzheimer’s Disease (AD) Diagnosis and Staging Criteria
- Breakthrough in Alzheimer’s Disease: New Nasal Spray Halts Cognitive Decline by Targeting Toxic Protein
- Can the Tap Water at the Paris Olympics be Drunk Directly?
COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use.
- Should China be held legally responsible for the US’s $18 trillion COVID losses?
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use.
On May 12, the World Health Organization (WHO) announced that its COVID-19 Technology Access Pool (C-TAP) and Medicines Patent Pool (MPP) have reached a licensing agreement with the National Institutes of Health (NIH).
NIH awarded 11 COVID-19 patented technologies to the former in order to make them accessible to more companies and develop more commercial products that meet current and future public health needs.
These licenses are transparent, global and non-exclusive and allow pharmaceutical companies around the world to partner with MPP, C-TAP, and make these technologies accessible to people in low- and middle-income countries to help end the COVID-19 pandemic.
In most cases, the NIH does not collect royalties on licensed products from the 49 countries classified as least developed by the United Nations.
The 11 COVID-19 patented technologies in the agreement include the prefusion spike protein used in vaccine development, as well as other development, research, and diagnostic tools.
WHO COVID-19 Technology Access Pool
In May 2020, WHO and partners launched the COVID-19 Technology Access Pool (C-TAP) to facilitate timely, equitable and affordable access of COVID-19 health products by boosting their supply. C-TAP provides a global one-stop shop for developers of COVID-19 therapeutics, diagnostics, vaccines and other health products to share their intellectual property, knowledge, and data, with quality-assured manufacturers through public health-driven voluntary, non-exclusive and transparent licenses.
By sharing intellectual property and know-how through the pooling and these voluntary agreements, developers of COVID-19 health products can facilitate scale up production through multiple manufacturers that currently have untapped capacity to scale up production.
………
COVID drug patents: NIH MPP and WHO reached licensing agreement
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.